Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

WuXi AppTec Co., Ltd. (2359.HK)

HKSE - HKSE Delayed Price. Currency in HKD
101.300-2.000 (-1.94%)
At close: 04:08PM HKT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close103.300
Open103.800
Bid100.500 x 0
Ask101.300 x 0
Day's Range100.200 - 104.300
52 Week Range57.900 - 137.700
Volume1,597,062
Avg. Volume2,665,883
Market Cap314.75B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.62 (1.00%)
Ex-Dividend DateMay 30, 2022
1y Target Est152.91
  • PR Newswire

    WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index

    WuXi AppTec, a leading global provider of R&D and manufacturing services that enables the global pharmaceutical and healthcare industry, today announced that it has been included in the 2022 Dow Jones Sustainability™ World Index (DJSI). This demonstrates the company's strong performance and commitment to Environmental, Social and Governance (ESG) initiatives.

  • PR Newswire

    WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan

    WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services for the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, announced that it is a recipient of the 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan, a global research & consulting firm that helps customers accelerate growth. This marks the sixth consecut

  • PR Newswire

    WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion

    WuXi AppTec (stock code: 603259.SH / 2359.HK), a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries to advance discoveries and deliver groundbreaking treatments to patients, is pleased to announce its financial results for the third quarter and nine months ended September 30, 2022 ("Reporting Period").

Advertisement
Advertisement